You are here

  • Home
  • Archive
  • Volume 6, Issue 4
  • Malaria prophylaxis with atovaquone-proguanil caused fewer gastrointestinal adverse events than chloroquine-proguanil

Article Text

Article menu
Download PDFPDF
Therapeutics
Malaria prophylaxis with atovaquone-proguanil caused fewer gastrointestinal adverse events than chloroquine-proguanil

https://doi.org/10.1136/ebm.6.4.118

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) Lancet 356, 1888. Høgh B, Clarke PD, Camus D, et al, and the Malarone International Study Team.. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study.. Dec 2;. :. –94.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In travellers who are not immune to malaria, is malaria prophylaxis with atovaquone proguanil equivalent to that with chloroquine proguanil for adverse events (AEs)?

    Design

    Randomised (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with follow up at 7, 28, and 60 days after leaving a malaria endemic area.

    Setting

    21 travel clinics in Denmark, the UK, France, Germany, the Netherlands, South Africa, and Canada.

    Participants

    1083 participants (mean age 36 y, 52% men, 96% white) who weighed >50 kg, were age ≥14 years, were in good health, and planned to travel ≤28 days in Africa (63%) or other Plasmodium falciparum endemic areas. Exclusion criteria included a history of seizures; psychiatric or neurological disorders; cardiac, …

    View Full Text

    Footnotes

    • Sources of funding: Ontario Ministry of Health; PSI; Glaxo Wellcome.

    • For correspondence: Malarone Publication Coordinator, Room 50-3505B, Glaxo Wellcome Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA. Fax +1 919 315 0377.

    • ↵* See glossary.